Table 2

Clinical predictors of erythroid responses for patients receiving EPO (Step 1/2)

VariableTotal patients (n = 73)Responders, percentage (n = 25)P
Age    
    < 65 y 10 20  
    ≥ 65 y 63 37 .48 
Sex    
    Male 48 40  
    Female 25 24 .21 
FAB subtype    
    RA, RARS 51 45  
    RAEB 21 10 .006 
EPO level    
    < 200 mU/mL 53 45  
    > 200 mU/mL 19 .002 
Cytogenetics*    
    Good, intermediate 57 42  
    Poor 13 .14 
IPSS score    
    Low/intermediate-1 61 34  
    Intermediate-2/high 11 27 .74 
Prior transfusion support    
    Yes 29 31  
    No 43 37 .62 
VariableTotal patients (n = 73)Responders, percentage (n = 25)P
Age    
    < 65 y 10 20  
    ≥ 65 y 63 37 .48 
Sex    
    Male 48 40  
    Female 25 24 .21 
FAB subtype    
    RA, RARS 51 45  
    RAEB 21 10 .006 
EPO level    
    < 200 mU/mL 53 45  
    > 200 mU/mL 19 .002 
Cytogenetics*    
    Good, intermediate 57 42  
    Poor 13 .14 
IPSS score    
    Low/intermediate-1 61 34  
    Intermediate-2/high 11 27 .74 
Prior transfusion support    
    Yes 29 31  
    No 43 37 .62 

RA indicates refractory anemia.

*

IPSS risk category.

Eight patients lacking central cytogenetic review had institutional cytogenetic reports reviewed.

or Create an Account

Close Modal
Close Modal